Exclusive Summary

• - EU27 and US registrations plus US FDA GMP confer high compliance and market access, enabling rapid distribution rollouts.
• - Addresses high-burden indications (pancreatic cancer, NSCLC, breast cancer) with widespread NCCN/ESMO inclusion—pancreatic cancer as first-line standard—ensuring steady clinical demand.
• - Core patents have expired in major markets; manufacturing complexity keeps generic competition limited, offering differentiation and early-mover advantages.
• - Typical 20–50% price reductions versus originator (market- and tender-dependent) deliver meaningful cost savings and improved access.
• - Open to Africa and India partnerships; EU/US registrations and multi-pharmacopoeia API compliance strengthen tender competitiveness and channel expansion.